Gastrointestinal stromal tumours - sunitinib
Sunitinib for the treatment of gastrointestinal stromal tumours
Summary
Sunitinib is recommended as a possible treatment for people with unresectable or metastatic malignant gastrointestinal stromal tumours if they have already tried imatinib treatment but it has not worked or was not suitable. The manufacturer of sunitinib has agreed to cover the cost of the drug for t ...
Guidance documents
Implementing this guidance
Other information
We will consult on our review plans for this guidance in August 2011
About this guidance
Technology appraisals TA179
Issued: September 2009
How this guidance was produced